what will happen to the ph of a sodium chloride solution when kcl is added?
Rx only
Potassium Chloride in 5% Dextrose and Sodium Chloride Injection, USP
Flexible Plastic Container
Intravenous solutions with potassium chloride (I.Five. solutions with KCl) are sterile and nonpyrogenic solutions in water for injection. They are for administration by intravenous infusion simply.
See Tables for summary of content and characteristics of these solutions.
The solutions contain no bacteriostat, antimicrobial amanuensis or added buffer and each is intended only for use as a unmarried-dose injection. When smaller doses are required the unused portion should be discarded.
These solutions are parenteral fluid, nutrient and/or electrolyte replenishers.
Dextrose, USP is chemically designated D-glucose, monohydrate (Chalf dozenH12O6 • H2O), a hexose sugar freely soluble in h2o. It has the following structural formula:
Potassium Chloride, USP is chemically designated KCl, a white granular pulverisation freely soluble in water.
Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water.
Water for Injection, USP is chemically designated H2O.
The flexible plastic container is fabricated from a specially formulated polyvinylchloride. H2o tin permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; all the same, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will pb to minor losses in the moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will atomic number 82 to clinically pregnant changes within the expiration period.
When administered intravenously, these solutions provide a source of water and potassium chloride with carbohydrate (dextrose) and sodium chloride. Meet HOW SUPPLIED department for specific concentrations of these various solutions.
Solutions containing carbohydrate in the class of dextrose restore blood glucose levels and provide calories. Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein-sparing action. Dextrose injected parenterally undergoes oxidation to carbon dioxide and h2o.
Intravenous solutions containing potassium chloride are particularly intended to provide needed potassium cation (Thousand+). Potassium is the chief cation of body cells (160 mEq/liter of intracellular h2o). Information technology is constitute in low concentration in plasma and extracellular fluids (3.5 to 5.0 mEq/liter in a salubrious adult). Potassium plays an important office in electrolyte remainder. Normally about fourscore to xc% of the potassium intake is excreted in the urine; the residue in the stools and to a pocket-size extent, in the perspiration. The kidney does not conserve potassium well so that during fasting or in patients on a potassium-gratis diet, potassium loss from the body continues resulting in potassium depletion. A deficiency of either potassium or chloride volition lead to a deficit of the other.
Sodium chloride in water dissociates to provide sodium (Na+) and chloride (Cl−) ions. Sodium (Na+) is the principal cation of the extracellular fluid and plays a big function in the therapy of fluid and electrolyte disturbances. Chloride (Cl−) has an integral role in buffering activity when oxygen and carbon dioxide substitution occurs in the red blood cells. The distribution and excretion of sodium (Na+) and chloride (Cl−) are largely under the control of the kidney which maintains a residuum between intake and output.
Water is an essential elective of all trunk tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirement ranges from two to iii liters (i.0 to 1.v liters each for insensible water loss past perspiration and urine product).
H2o balance is maintained by various regulatory mechanisms. H2o distribution depends primarily on the concentration of electrolytes in the torso compartments and sodium (Na+) plays a major function in maintaining physiologic equilibrium.
These solutions are indicated in patients requiring parenteral administration of potassium chloride with minimal carbohydrate calories and sodium chloride.
Solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered.
Solutions which contain potassium ions should be used with great intendance, if at all, in patients with hyperkalemia, astringent renal failure and in conditions in which potassium retentivity is present.
To avoid potassium intoxication, exercise non infuse these solutions rapidly. In patients with severe renal insufficiency or adrenal insufficiency, administration of potassium chloride may cause potassium intoxication.
Solutions containing sodium ions should be used with great care, if at all, in patients with congestive eye failure, severe renal insufficiency and in clinical states in which there exists edema with sodium memory.
In patients with diminished renal function, assistants of solutions containing sodium or potassium ions may outcome in sodium or potassium retention.
The intravenous assistants of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.
The risk of dilutional states is inversely proportional to the electrolyte concentration of administered parenteral solutions. The run a risk of solute overload causing congested states with peripheral and pulmonary edema is straight proportional to the electrolyte concentrations of such solutions.
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base rest during prolonged parenteral therapy or whenever the status of the patient warrants such evaluation.
Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.
Caution must be exercised in the administration of parenteral fluids, specially those containing sodium ions, to patients receiving corticosteroids or corticotropin.
Potassium replacement therapy should be guided primarily by serial electrocardiograms. Plasma potassium levels are not necessarily indicative of tissue potassium levels.
High plasma concentrations of potassium may crusade decease through cardiac depression, arrhythmias or abort.
Potassium-containing solutions should be used with caution in the presence of cardiac disease, particularly in digitalized patients or in the presence of renal illness.
Intendance should be exercised to insure that the needle (or catheter) is well within the lumen of the vein and that extravasation does not occur.
Do non administrate unless solution is clear and container is undamaged. Discard unused portion.
Carcinogenesis, Mutagenesis, Impairment of Fertility:
Studies with solutions from flexible plastic containers accept not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.
Pregnancy Category C. Animal reproduction studies have not been conducted with dextrose, potassium chloride or sodium chloride. Information technology is as well not known whether dextrose, potassium chloride or sodium chloride can cause fetal damage when administered to a pregnant woman or tin can affect reproduction capacity. Dextrose, potassium chloride or sodium chloride should exist given to a significant woman only if clearly needed.
Nursing Mothers:
Caution should be exercised when solutions from flexible plastic containers are administered to a nursing mother.
Pediatric Utilise:
The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. In neonates or very small infants the volume of fluid may affect fluid and electrolyte balance.
Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low nascency weight infants.
In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.
Geriatric Use:
An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In full general, dose pick for an elderly patient should exist cautious, ordinarily starting at the depression end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Sodium and potassium ions are known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Considering elderly patients are more likely to accept decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Reactions which may occur considering of the solutions or technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for test if deemed necessary.
Nausea, airsickness, abdominal hurting and diarrhea take been reported with potassium therapy. The signs and symptoms of potassium intoxication include paresthesias of the extremities, flaccid paralysis, listlessness, mental confusion, weakness and heaviness of the legs, hypotension, cardiac arrhythmias, middle block, electrocardiographic abnormalities such as disappearance of P waves, spreading and slurring of the QRS circuitous with development of a biphasic bend and cardiac arrest.
Potassium-containing solutions are intrinsically irritating to tissues. Therefore, extreme care should be taken to avoid perivascular infiltration. Local tissue necrosis and subsequent sloughing may result if extravasation occurs. Chemical phlebitis and venospasm have as well been reported.
Should perivascular infiltration occur, I.V. administration at that site should exist discontinued at once. Local infiltration of the affected area with procaine hydrochloride, 1%, to which hyaluronidase may be added, volition oftentimes reduce venospasm and dilute the potassium remaining in the tissues locally. Local application of heat may too be helpful.
In the event of potassium overdosage, discontinue the infusion immediately and institute intensive corrective therapy to reduce serum potassium levels. See WARNINGS and PRECAUTIONS .
These solutions should be administered but past intravenous infusion and as directed by the physician. The dose and rate of injection are dependent upon the historic period, weight and clinical condition of the patient. If the serum potassium level is greater than 2.5 mEq/liter, potassium should be given at a rate non to exceed 10 mEq/hour in a concentration less than 30 mEq/liter. Somewhat faster rates and greater concentrations (normally up to twoscore mEq/liter) of potassium may be indicated in patients with more severe potassium deficiency. The total 24-hr dose should not generally exceed 200 mEq of potassium.
As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, especially neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.
Drug Interactions
Additives may be incompatible. Consult with chemist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.
Parenteral drug products should be inspected visually for particulate affair and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS .
To Open
Tear outer wrap at notch and remove solution container. If supplemental medication is desired, follow directions beneath before preparing for administration. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity volition diminish gradually.
To Add Medication
- Set up additive port.
- Using hygienic technique and an additive commitment needle of appropriate length, puncture resealable additive port at target expanse, inner diaphragm and inject. Withdraw needle after injecting medication.
- The condiment port may be protected past roofing with an additive cap.
- Mix container contents thoroughly.
Preparation for Administration
(Apply aseptic technique)
- Shut flow control clench of administration set.
- Remove cover from outlet port at lesser of container.
- Insert piercing pin of administration ready into port with a twisting movement until the set is firmly seated. NOTE: See full directions on administration set carton.
- Suspend container from hanger.
- Squeeze and release drip bedroom to institute proper fluid level in sleeping room.
- Open up flow control clamp and clear air from set. Shut clamp.
- Attach prepare to venipuncture device. If device is not indwelling, prime number and make venipuncture.
- Regulate rate of administration with flow control clench.
WARNING: Practise not utilize flexible container in series connections.
Intravenous solutions with potassium chloride (I.Five. solution with KCl) are supplied in unmarried-dose flexible plastic containers. See Tables:
May comprise HCl for pH adjustment.
Store at twenty to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]
Protect from freezing.
Revised: April, 2009
Printed in U.s.a. EN-2100
Hospira, Inc., Lake Forest, IL 60045 U.s.a.
20 mEq POTASSIUM
1000 mL
NDC 0409-7107-09
twenty
mEq
POTASSIUM
CHLORIDE
in v% Dextrose and
0.ix% Sodium Chloride
Injection, USP
EACH 100 mL CONTAINS POTASSIUM
CHLORIDE 149 mg; SODIUM CHLORIDE 900 mg;
DEXTROSE, HYDROUS v grand IN WATER FOR
INJECTION. MAY CONTAIN HCl FOR pH
ADJUSTMENT. ELECTROLYTES PER 1000 mL
(Not INCLUDING IONS FOR pH ADJUSTMENT):
POTASSIUM 20 mEq; SODIUM 154 mEq;
CHLORIDE 174 mEq.
600 mOsmol/LITER (CALC.)
pH iv.2 (3.v to vi.five)
ADDITIVES MAY Be INCOMPATIBLE.
CONSULT WITH PHARMACIST, IF
AVAILABLE. WHEN INTRODUCING
ADDITIVES, Employ Hygienic TECHNIQUE,
MIX THOROUGHLY AND Exercise NOT STORE.
SINGLE-DOSE CONTAINER. FOR I.V. Apply.
USUAL DOSAGE: Meet INSERT. STERILE,
NONPYROGENIC. Utilize Only IF SOLUTION IS
CLEAR AND CONTAINER IS UNDAMAGED.
MUST Not BE USED IN Series CONNECTIONS.
Rx only
iii
v
CONTAINS DEHP
©HOSPIRA 2004
IM-0031 (four/04)
PRINTED IN The states
HOSPIRA, INC., LAKE FOREST, IL 60045 USA
Hospira
forty mEq POTASSIUM
thousand mL
NDC 0409-7109-09
40
mEq
POTASSIUM
CHLORIDE
in five% Dextrose and
0.9% Sodium Chloride
Injection, USP
EACH 100 mL CONTAINS POTASSIUM
CHLORIDE 298 mg; SODIUM CHLORIDE 900 mg;
DEXTROSE, HYDROUS 5 g IN WATER FOR
INJECTION. MAY Incorporate HCl FOR pH
Adjustment. ELECTROLYTES PER 1000 mL
(Not INCLUDING IONS FOR pH ADJUSTMENT):
POTASSIUM twoscore mEq; SODIUM 154 mEq;
CHLORIDE 194 mEq.
640 mOsmol/LITER (CALC.)
pH 4.2 (iii.v to 6.5)
ADDITIVES MAY Exist INCOMPATIBLE.
CONSULT WITH PHARMACIST, IF
AVAILABLE. WHEN INTRODUCING
ADDITIVES, Employ ASEPTIC TECHNIQUE,
MIX THOROUGHLY AND DO NOT Store.
Unmarried-DOSE CONTAINER. FOR I.V. USE.
USUAL DOSAGE: Run across INSERT. STERILE,
NONPYROGENIC. USE Only IF SOLUTION IS
CLEAR AND CONTAINER IS UNDAMAGED.
MUST Non Be USED IN SERIES CONNECTIONS.
Rx Merely
3
v
CONTAINS DEHP
©HOSPIRA 2004
IM-0034 (four/04)
PRINTED IN Us
HOSPIRA, INC., LAKE Wood, IL 60045 The states
Hospira
thirty mEq POTASSIUM
k mL
NDC 0409-7903-09
30
mEq
POTASSIUM
CHLORIDE
in five% Dextrose and
0.45% Sodium Chloride
Injection, USP
EACH 100 mL CONTAINS POTASSIUM
CHLORIDE 224 mg; SODIUM CHLORIDE 450 mg;
DEXTROSE, HYDROUS five m IN H2o FOR
INJECTION. MAY CONTAIN HCl FOR pH
Adjustment. ELECTROLYTES PER thousand mL
(Non INCLUDING IONS FOR pH ADJUSTMENT):
POTASSIUM 30 mEq; SODIUM 77 mEq;
CHLORIDE 107 mEq.
467 mOsmol/LITER (CALC.)
pH 4.2 (3.v to vi.5)
ADDITIVES MAY Be INCOMPATIBLE.
CONSULT WITH Chemist, IF
AVAILABLE. WHEN INTRODUCING
ADDITIVES, USE ASEPTIC TECHNIQUE,
MIX THOROUGHLY AND DO Not STORE.
Unmarried-DOSE CONTAINER. FOR I.5. USE.
USUAL DOSAGE: SEE INSERT. STERILE,
NONPYROGENIC. Use Merely IF SOLUTION IS
Articulate AND CONTAINER IS UNDAMAGED.
MUST NOT BE USED IN SERIES CONNECTIONS.
Rx Merely
3
v
CONTAINS DEHP
©HOSPIRA 2004
IM-0086 (four/04)
PRINTED IN Us
HOSPIRA, INC., LAKE Woods, IL 60045 USA
Hospira
40 mEq POTASSIUM
chiliad mL
NDC 0409-7904-09
40
mEq
POTASSIUM
CHLORIDE
in 5% Dextrose and
0.45% Sodium Chloride
Injection, USP
EACH 100 mL CONTAINS POTASSIUM
CHLORIDE 298 mg; SODIUM CHLORIDE 450 mg;
DEXTROSE, HYDROUS five g IN Water FOR
INJECTION. MAY CONTAIN HCl FOR pH
Aligning. ELECTROLYTES PER 1000 mL
(NOT INCLUDING IONS FOR pH ADJUSTMENT):
POTASSIUM twoscore mEq; SODIUM 77 mEq;
CHLORIDE 117 mEq.
487 mOsmol/LITER (CALC.)
pH 4.2 (three.five to 6.5)
ADDITIVES MAY Be INCOMPATIBLE.
CONSULT WITH Pharmacist, IF
Available. WHEN INTRODUCING
ADDITIVES, USE ASEPTIC TECHNIQUE,
MIX THOROUGHLY AND DO NOT STORE.
SINGLE-DOSE CONTAINER. FOR I.V. USE.
USUAL DOSAGE: Run across INSERT. STERILE,
NONPYROGENIC. USE Simply IF SOLUTION IS
Clear AND CONTAINER IS UNDAMAGED.
MUST NOT BE USED IN Series CONNECTIONS.
Rx ONLY
3
five
CONTAINS DEHP
©HOSPIRA 2004
IM-0087 (4/04)
PRINTED IN USA
HOSPIRA, INC., LAKE FOREST, IL 60045 USA
Hospira
30 mEq POTASSIUM
k mL
NDC 0409-7991-09
thirty
mEq
POTASSIUM
CHLORIDE
in 5% Dextrose and
0.225% Sodium Chloride
Injection, USP
EACH 100 mL CONTAINS POTASSIUM CHLORIDE
224 mg; SODIUM CHLORIDE 225 mg; DEXTROSE,
HYDROUS five chiliad IN WATER FOR INJECTION. MAY
Comprise HCl FOR pH ADJUSTMENT.
ELECTROLYTES PER 1000 mL (Not INCLUDING
IONS FOR pH ADJUSTMENT): POTASSIUM
30 mEq; SODIUM 38.v mEq; CHLORIDE 68.5 mEq.
389 mOsmol/LITER (CALC.)
pH four.2 (3.five to vi.5)
ADDITIVES MAY BE INCOMPATIBLE.
CONSULT WITH PHARMACIST, IF Available.
WHEN INTRODUCING ADDITIVES,
Utilise Hygienic TECHNIQUE, MIX THOROUGHLY
AND DO NOT STORE.
SINGLE-DOSE CONTAINER. FOR I.V. USE.
USUAL DOSAGE: See INSERT. STERILE,
NONPYROGENIC. USE ONLY IF SOLUTION IS CLEAR
AND CONTAINER IS UNDAMAGED. MUST NOT BE
USED IN SERIES CONNECTIONS.
Rx ONLY
3
v
CONTAINS DEHP
©HOSPIRA 2004
IM-0088 (4/04)
PRINTED IN United states of america
HOSPIRA, INC., LAKE FOREST, IL 60045 United states
Hospira
40 mEq POTASSIUM
1000 mL
NDC 0409-7992-09
40
mEq
POTASSIUM
CHLORIDE
in 5% Dextrose and
0.225% Sodium Chloride
Injection, USP
EACH 100 mL CONTAINS POTASSIUM CHLORIDE
298 mg; SODIUM CHLORIDE 225 mg; DEXTROSE,
HYDROUS five yard IN WATER FOR INJECTION. MAY
CONTAIN HCl FOR pH Aligning.
ELECTROLYTES PER 1000 mL (NOT INCLUDING
IONS FOR pH Adjustment): POTASSIUM
40 mEq; SODIUM 38.five mEq; CHLORIDE 78.5 mEq.
409 mOsmol/LITER (CALC.)
pH 4.2 (3.5 to 6.5)
ADDITIVES MAY Exist INCOMPATIBLE.
CONSULT WITH Pharmacist, IF Bachelor.
WHEN INTRODUCING ADDITIVES,
Use ASEPTIC TECHNIQUE, MIX THOROUGHLY
AND Practise NOT Store.
Single-DOSE CONTAINER. FOR I.5. Use.
USUAL DOSAGE: Meet INSERT. STERILE,
NONPYROGENIC. Apply ONLY IF SOLUTION IS Clear
AND CONTAINER IS UNDAMAGED. MUST NOT BE
USED IN Series CONNECTIONS.
Rx Simply
3
v
CONTAINS DEHP
©HOSPIRA 2004
IM-0089 (4/04)
PRINTED IN The states
HOSPIRA, INC., LAKE Wood, IL 60045 United states of america
Hospira
10 mEq POTASSIUM
1000 mL
NDC 0409-7993-09
10
mEq
POTASSIUM
CHLORIDE
in 5% Dextrose and
0.45% Sodium Chloride
Injection, USP
EACH 100 mL CONTAINS POTASSIUM
CHLORIDE 74.5 mg; SODIUM CHLORIDE 450 mg;
DEXTROSE, HYDROUS 5 one thousand IN WATER FOR
INJECTION. MAY Comprise HCl FOR pH
Adjustment.
ELECTROLYTES PER 1000 mL (NOT INCLUDING
IONS FOR pH ADJUSTMENT): POTASSIUM
10 mEq; SODIUM 77 mEq; CHLORIDE 87 mEq.
426 mOsmol/LITER (CALC.)
pH 4.2 (3.5 to 6.v)
ADDITIVES MAY BE INCOMPATIBLE.
CONSULT WITH PHARMACIST, IF Bachelor.
WHEN INTRODUCING ADDITIVES,
Employ ASEPTIC TECHNIQUE, MIX THOROUGHLY
AND Do NOT STORE.
Single-DOSE CONTAINER. FOR I.V. Use.
USUAL DOSAGE: Come across INSERT. STERILE,
NONPYROGENIC. USE Just IF SOLUTION IS
Clear AND CONTAINER IS UNDAMAGED.
MUST Not Be USED IN Series CONNECTIONS.
Rx But
3
v
CONTAINS
DEHP
PRINTED IN USA
©HOSPIRA 2004
IM-0090 (four/04)
HOSPIRA, INC., LAKE Forest, IL 60045 USA
Hospira
10 mEq POTASSIUM
500 mL
NDC 0409-7901-03
10
mEq
POTASSIUM
CHLORIDE
in 5% Dextrose and
0.225% Sodium Chloride Inj., USP
EACH 100 mL CONTAINS POTASSIUM CHLORIDE 149 mg; SODIUM
CHLORIDE 225 mg; DEXTROSE, HYDROUS 5 m IN H2o FOR INJECTION.
MAY Comprise HCl FOR pH Adjustment. ELECTROLYTES PER one thousand mL
(Non INCLUDING IONS FOR pH Aligning): POTASSIUM twenty mEq;
SODIUM 38.5 mEq; CHLORIDE 58.v mEq. 370 mOsmol/LITER (CALC.)
pH 4.2 (iii.5 to 6.5)
ADDITIVES MAY BE INCOMPATIBLE. CONSULT WITH
Pharmacist, IF AVAILABLE. WHEN INTRODUCING
ADDITIVES, USE Hygienic TECHNIQUE, MIX
THOROUGHLY AND DO NOT STORE.
SINGLE-DOSE CONTAINER. FOR I.V. Use. USUAL DOSAGE: SEE INSERT.
STERILE, NONPYROGENIC. Utilize ONLY IF SOLUTION IS Articulate AND
CONTAINER IS UNDAMAGED. MUST NOT BE USED IN Series
CONNECTIONS.
©HOSPIRA 2004
IM-0057 (four/04)
PRINTED IN The states
HOSPIRA, INC., LAKE Forest, IL 60045 The states
3
5
CONTAINS DEHP
Rx Only
Hospira
10 mEq POTASSIUM
500 mL
NDC 0409-7998-03
10
mEq
POTASSIUM
CHLORIDE
in 5% Dextrose and
0.3% Sodium Chloride Inj., USP
EACH 100 mL CONTAINS POTASSIUM CHLORIDE 149 mg; SODIUM
CHLORIDE 300 mg; DEXTROSE, HYDROUS 5 g IN H2o FOR
INJECTION. MAY Comprise HCl FOR pH Aligning.
ELECTROLYTES PER thou mL (NOT INCLUDING IONS FOR pH
Aligning): POTASSIUM 20 mEq; SODIUM 51 mEq; CHLORIDE 71
mEq. 395 mOsmol/LITER (CALC.)
pH 4.2 (3.five to 6.5)
ADDITIVES MAY Exist INCOMPATIBLE.
CONSULT WITH PHARMACIST, IF AVAILABLE.
WHEN INTRODUCING ADDITIVES, USE Hygienic TECHNIQUE, MIX
THOROUGHLY AND Exercise Not Store.
Single-DOSE CONTAINER. FOR I.5. USE. USUAL DOSAGE: SEE
INSERT. STERILE, NONPYROGENIC. USE
ONLY IF SOLUTION IS Articulate AND
CONTAINER IS UNDAMAGED. MUST Non
Be USED IN SERIES CONNECTIONS.
3
v
CONTAINS DEHP
PRINTED IN USA
Rx ONLY
©HOSPIRA 2004
IM-0096 (four/04)
HOSPIRA, INC., LAKE Forest, IL 60045 USA
Hospira
10 mEq POTASSIUM
500 mL
NDC 0409-7902-03
10
mEq
POTASSIUM
CHLORIDE
in five% Dextrose and
0.45% Sodium Chloride Inj., USP
EACH 100 mL CONTAINS POTASSIUM CHLORIDE 149 mg; SODIUM
CHLORIDE 450 mg; DEXTROSE, HYDROUS 5 g IN H2o
FOR INJECTION. MAY CONTAIN HCl FOR pH Aligning.
ELECTROLYTES PER chiliad mL (Not INCLUDING IONS FOR pH
ADJUSTMENT): POTASSIUM twenty mEq; SODIUM 77 mEq; CHLORIDE 97 mEq.
447 mOsmol/LITER (CALC.)
pH iv.two (3.5 to vi.5)
ADDITIVES MAY Exist INCOMPATIBLE. CONSULT WITH
PHARMACIST, IF AVAILABLE. WHEN INTRODUCING
ADDITIVES, USE ASEPTIC TECHNIQUE, MIX
THOROUGHLY AND DO NOT Store.
Unmarried-DOSE CONTAINER. FOR I.V. USE. USUAL DOSAGE: Encounter INSERT.
STERILE, NONPYROGENIC. Utilise ONLY IF SOLUTION IS CLEAR AND
CONTAINER IS UNDAMAGED. MUST Not Exist USED IN SERIES
CONNECTIONS.
Rx But
3
v
CONTAINS DEHP
PRINTED IN U.s.
©HOSPIRA 2004
IM-0065 (four/04)
HOSPIRA, INC., LAKE FOREST, IL 60045 USA
Hospira
10 mEq POTASSIUM
grand mL
NDC 0409-7997-09
x
mEq
POTASSIUM
CHLORIDE
in 5% Dextrose and
0.225% Sodium Chloride
Injection, USP
EACH 100 mL CONTAINS POTASSIUM
CHLORIDE 74.5 mg; SODIUM CHLORIDE 225 mg;
DEXTROSE, HYDROUS 5 g IN H2o FOR
INJECTION. MAY CONTAIN HCl FOR pH
ADJUSTMENT.
ELECTROLYTES PER thousand mL (NOT INCLUDING
IONS FOR pH ADJUSTMENT): POTASSIUM
10 mEq; SODIUM 38.5 mEq; CHLORIDE 48.five mEq.
349 mOsmol/LITER (CALC.)
pH four.2 (3.5 to 6.5)
ADDITIVES MAY Be INCOMPATIBLE.
CONSULT WITH PHARMACIST, IF Available.
WHEN INTRODUCING ADDITIVES,
Employ ASEPTIC TECHNIQUE, MIX THOROUGHLY
AND Exercise Non Shop.
Single-DOSE CONTAINER. FOR I.V. USE.
USUAL DOSAGE: SEE INSERT. STERILE,
NONPYROGENIC. USE But IF SOLUTION IS
Clear AND CONTAINER IS UNDAMAGED.
MUST Non Be USED IN SERIES CONNECTIONS.
Rx ONLY
3
5
CONTAINS DEHP
PRINTED IN USA
©HOSPIRA 2004
IM-0091 (4/04)
HOSPIRA, INC., LAKE Wood, IL 60045 United states
Hospira
TO Open TEAR AT NOTCH
2
HDPE
Practice NOT REMOVE FROM OVERWRAP UNTIL Ready FOR Utilise. AFTER REMOVING
THE OVERWRAP, Cheque FOR MINUTE LEAKS By SQUEEZING CONTAINER FIRMLY.
IF LEAKS ARE FOUND, DISCARD SOLUTION AS STERILITY MAY BE IMPAIRED.
RECOMMENDED STORAGE: ROOM TEMPERATURE (25°C). Avoid EXCESSIVE
HEAT. PROTECT FROM FREEZING. Come across INSERT.
98-4321-R14-3/98
Source: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d101c62c-9fd8-4bb6-e7a5-5074d189d35b
0 Response to "what will happen to the ph of a sodium chloride solution when kcl is added?"
Post a Comment